TQ05105 + TQB3617

TQ05105 + TQB3617 is an **investigational oral combination therapy** being studied for the treatment of **myelofibrosis**, particularly in patients with intermediate- and high-risk disease. TQ05105, also known as rovadicitinib, is a first-in-class, oral small molecule inhibitor targeting Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated protein kinase 1 (ROCK1). TQB3617 is a Bromodomain and Extra-Terminal (BET) inhibitor. The combination aims to utilize the anti-proliferative, anti-inflammatory, and anti-fibrotic effects through inhibition of these pathways. The regimen is under active clinical investigation, with oral administration on a 21-day cycle[1][3][6].

Other names

TQ05105 Tablets + TQB3617 Capsules